GAO, Ziyu, YANG, Xuebin, JONES, Elena, BINGHAM, Paul, SCRIMSHIRE, Alex, THORNTON, Paul and TRONCI, Giuseppe (2020). An injectable, self-healing and MMP-inhibiting hyaluronic acid gel via iron coordination. International Journal of Biological Macromolecules, 165 (B), 2022-2029. [Article]
Documents
27389:559047
PDF
Fe-HA gel Manuscript_IJBM_accepted.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Fe-HA gel Manuscript_IJBM_accepted.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Download (3MB) | Preview
27389:559058
PDF
Bingham-InjectableSelfhealingMMP(SuppMat).pdf - Supplemental Material
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Bingham-InjectableSelfhealingMMP(SuppMat).pdf - Supplemental Material
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Download (306kB) | Preview
Abstract
Regulating the activity of matrix metalloproteinases (MMPs) is a potential strategy for osteoarthritis (OA) therapy, although delivering this effect in a spatially and temporally localised fashion remains a challenge. Here, we report an injectable and self-healing hydrogel enabling factor-free MMP regulation and biomechanical competence in situ. The hydrogel is realised within one minute upon room temperature coordination between hyaluronic acid (HA) and a cell-friendly iron-glutathione complex in aqueous environment. The resultant gel displayed up to 300% in shear strain and tolerance towards ATDC 5 chondrocytes, in line with
21 the elasticity and biocompatibility requirements for connective tissue application. Significantly enhanced inhibition of MMP-13 activity was achieved after 12 hours in vitro, compared with a commercial HA injection (OSTENIL® PLUS). Noteworthy, 24-hour incubation of a clinical synovial fluid sample collected from a late-stage OA patient with the reported hydrogel was still shown to downregulate synovial fluid MMP activity (100.0±17.6 % à 81.0±7.5 %), with at least comparable extent to the case of the OSTENIL® PLUS-treated SF group (100.0±17.6 % à 92.3±27.3 %). These results therefore open up new possibilities in the use of HA as both mechanically-competent hydrogel as well as a mediator of MMP regulation for OA therapy.
More Information
Statistics
Downloads
Downloads per month over past year
Metrics
Altmetric Badge
Dimensions Badge
Share
Actions (login required)
View Item |